Anonymous ID: 40e439 Nov. 12, 2021, 4:45 p.m. No.14986600   🗄️.is 🔗kun   >>6713 >>6782 >>6810

>>14986352

>>14986283

>>14986274

>>14986132

>Glen de Vries

>>14986172

 

Glen de Vries

 

Life Sciences & Healthcare Vice-Chair for Dassault Systèmes

 

Medidata co-founder Glen de Vries was named Life Sciences & Healthcare Vice-Chair for Dassault Systèmes in July 2021.

 

de Vries drove Medidata’s mission, from 1999 through Medidata’s acquisition by Dassault Systèmes in 2019, of “powering smarter treatments and healthier people” by advancing transformation in clinical research with technology, non-traditional ways of thinking, and industry collaboration. Over more than two decades, de Vries worked with the largest pharma companies, small biotechs, and medical device companies across tens-of-thousands of clinical trials.

 

As the Vice-Chair of Life Sciences and Healthcare, he leverages the Medidata platform, including billions of records from millions of patient volunteers across virtually every therapeutic area, along with the broader scientific, manufacturing and virtual twin capabilities of 3DS to transform not just the creation of new therapies, but their ultimate delivery to patients around the world.

 

Articles and papers by de Vries have appeared in Applied Clinical Trials, Cancer, The Journal of Urology, Molecular Diagnostics, and other journals. He serves as a trustee of Carnegie Mellon University and is the author of The Patient Equation (de Vries & Blachman, 2020).

 

de Vries received his undergraduate degree in molecular biology and genetics from Carnegie Mellon University, worked as a research scientist at the Columbia Presbyterian Medical Center, and studied computer science at New York University's Courant Institute of Mathematics.

 

You can follow him on social media at @CaptainClinical

 

https://www.medidata.com/en/leadership/glen-de-vries

Anonymous ID: 40e439 Nov. 12, 2021, 5:06 p.m. No.14986782   🗄️.is 🔗kun

>>14986274

>>14986283

>>14986600

>>14986713

 

Perhaps the Most Pivotal Clinical Trial in Modern History & The Sponsor Opts for RAVE & Associated Medidata eClinical Suite

 

July 24, 2020

 

Dassault Systems made a big move into the clinical trials technology space when the French product lifecycle management technology corporation acquired the market’s leading electronic data capture software company Medidata for $5.8 billion. Well the acquisition certainly propelled the French company directly into the clinical trials world. Now Medidata announces that Moderna has selected the Medidata suite of eClinical technologies including electronic data capture product Rave to support the Phase 3 clinical trials of mRNA-1273 for the COVID-19 pandemic. Perhaps the most important clinical trials of this era, and Rave is selected. Moreover, the study incorporates “virtualization” allowing participants to use their own devices if they choose. Clearly, Moderna signaled to the market which eClinical suite they believed to be most superior.

 

Medidata Selected

 

As announced in recent press release, the Medidata’s suite of technologies is supporting the advancement of Moderna’s mRNA-1273 clinical trials, including the Phase 3 trial, which is expected to enroll 30,000 participants. The Medidata and Moderna teams are moving forward with the speed and urgency necessitated by the globa…

 

[rest behind subscrition paywall]

 

https://trialsitenews.com/perhaps-the-most-pivotal-clinical-trial-in-modern-history-the-sponsor-opts-for-rave-associated-medidata-eclinical-suite/